WilmerHale Advises Arteaus Therapeutics in Sale of Emgality Royalty to Royalty Pharma for $260M

• 4.2.2019

On April 1, 2019, Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded by Atlas Venture and OrbiMed, announced that Arteaus has sold its royalty interest on future global net sales of Eli Lilly and Company’s (NYSE: LLY) Emgality (galcanezumab), an anti-CGRP antibody for the prevention of migraine, to Royalty Pharma for $260 million.

WilmerHale represented Arteaus in the deal, with a team led by Steve Singer and Joe Conahan that included Julie Hogan Rodgers, John Sigel, Brandt Tierney and Tyler Rostock.